Reviewmoderate evidence
Elimination of the Black Box Warning on Menopausal Hormone Therapy.
Obstetrics and gynecology·May 1, 2026·PMID 41687116
Why it mattersThe removal of the black box warning and shift to individualized, product-specific labeling directly impacts how clinicians counsel postmenopausal patients on hormone therapy, enabling more nuanced benefit-risk discussions and potentially reducing barriers to appropriate MHT use.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled